.
.
.
.
Products
Applications & Insights
Knowledge & Support
About QIAGEN
Quick Order
0
Cart
My QIAGEN
Experiment Configurator
Discovery & Translational Research
Diagnostics & Clinical Research
Human ID & Forensics
Next-Generation Sequencing
Instruments & Automation
Informatics & Data
Services
OEM by QIAGEN
Top Sellers
New Solutions
Shop
Applications & Insights Overview
Research & Technology
Diagnostic & Clinical
Applied & Industrial
Digital Tools & Platforms
Plan your experiment
Knowledge & Support Overview
Service Solutions
Events & Webinars
Safety Data Sheets
Knowledge Hub
Quality, Environmental, Health & Safety
Product & Technical Support
Ordering Support
Resources
Product FAQ
About Us
Careers
Investor Relations
Newsroom
Customer stories
Sustainability
Compliance
Contact Us
TB Management
QuantiFERON-TB Gold Plus
Transplant
QuantiFERON Transplant
artus Viral Load
Infectious Disease
QIAstat-Dx Syndromic Testing
Oncology
therascreen Solid Tumor
ipsogen Leukemia
Circulating Tumor Cells
DNA Damage Response
Sexual & Reproductive Health
Cervical Cancer Screening
Maternal/Fetal Testing
STI Testing
Sample Processing
Solutions for Laboratory-Developed Tests
Looking for a quick way to design experiments?
Try the Workflow Configurator. A convenient tool to build experimental workflows and find products to match your needs.
Welcome to My QIAGEN
Dashboard
Account
Orders
Log Out
icon_0147_cc_gen_global-s
NO
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia (Plurinational State of)
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei Darussalam (Brunei)
Bulgaria
Burkina Faso
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Federated States of Micronesia
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iraq
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libia
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
North Macedonia
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Rwanda
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Timor-Leste
Tonga
Trinidad and Tobago
Tunisia
Türkiye
Turkmenistan
Turks and Caicos Islands
Tuvalu
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States Minor Outlying Islands
United States of America
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
icon_0058_speech_bubble-s
ZH
Chinese (Simplified, PRC)
Japanese (Japan)
Korean (Korea)
French
German
Spanish
English
Welcome to QIAGEN!
You can accept or revoke the cookies used on this website at any time with the selection below or by adjusting your cookie settings. For complete details about our cookies, see our
Cookie Policy
.
Customize
Only necessary
Accept all
ipsogen Leukemia
Home
产品
Diagnostics & Clinical Research
Oncology
ipsogen Leukemia
ipsogen
JAK2 MutaScreen Kits
ipsogen
JAK2 MutaScreen Kits
采用real-time PCR对JAK2 V617F/G1849T突变进行半定量检测
产品
产品详情
资源
Products
仅作研究用途。不用于诊断程序。任何表述或表示都并非旨在提供诊断、预防或治疗疾病的信息。
ipsogen
JAK2 MutaScreen Kit (10)
Cat. No. / ID. / ID.
673012
For 10 reactions: V617F Positive Control, V617F Negative Control, V617F Cut-Off Sample, Primers and Probes Mix JAK2 wild-type and JAK2 V617F
Copy order details
登录
ipsogen
JAK2 MutaScreen Kit (24)
Cat. No. / ID. / ID.
673013
For 24 reactions: V617F Positive Control, V617F Negative Control, V617F Cut-Off Sample, Primers and Probes Mix JAK2 wild-type and JAK2 V617F
Copy order details
登录
ipsogen
JAK2 MutaScreen RS Kit (19)
Cat. No. / ID. / ID.
673113
For 19 reactions: V617F Positive Control, V617F Negative Control, V617F Reference Scale, Primers and Probes Mix JAK2 wild-type and JAK2 V617F
Copy order details
登录
特点
可靠的半定量检测
多重分析,无需优化
即用型解决方案,便利的工作流程
产品详情
ipsogen
JAK2 MutaScreen Kits仅适用于科研,不可用于诊断。该试剂盒可用于Rotor-Gene Q实时荧光定量PCR分析仪或其他real-time PCR仪的real-time PCR实验。该试剂盒中的试剂经过优化,能够对基因组DNA中的JAK2 V617F/G1849T突变进行灵敏、可靠的半定量检测。
绩效
为确保检测的准确性,
ipsogen
NJAK2 MutaScreen Kit已经过优化,利用DNA阳性和阴性对照,检测JAK2 V617F/G1849T突变(参见
Representative allelic discrimination experiments for qualitative detection of the JAK2 V617F/G1849T mutation in genomic DNA
和
Representative allelic discrimination experiments for semi-quantitative detection of the JAK2 V617F/G1849T mutation in genomic DNA
)。
ipsogen
JAK2 MutaScreen Kits的样本阳性DNA浓度检测阈限为2%,推荐的起始样本DNA量最少为25 ng。
查看图表
JAK2 mutation site identification.
Representative allelic discrimination experiments for qualitative detection of the JAK2 V617F/G1849T mutation in genomic DNA.
Representative allelic discrimination experiments for semi-quantitative detection of the JAK2 V617F/G1849T mutation in genomic DNA.
原理
ipsogen
JAK2 MutaScreen Kits为即用型试剂盒,能够对基因组DNA中SNP导致的的JAK2 V617F/G1849T体细胞突变进行半定量检测分析(参见
JAK2 mutation site identification
)。该试剂盒能够获得可靠、可重复性的结果。
ipsogen
JAK2 MutaScreen Kits提供JAK2 V617F的DNA检测临界样本(COS)、DNA阳性对照(PC)和阴性对照(NC)。使用检测临界样本和对照能够实现准确的基因分型分析。
ipsogen
JAK2 MutaScreen RS Kit提供V617F的参比。
查看图表
Representative allelic discrimination experiments for semi-quantitative detection of the JAK2 V617F/G1849T mutation in genomic DNA.
JAK2 mutation site identification.
Representative allelic discrimination experiments for qualitative detection of the JAK2 V617F/G1849T mutation in genomic DNA.
程序
第一步是抽提总DNA,并检测其量与品质。第二步是通过real-time PCR扩增DNA。
ipsogen
JAK2 MutaScreen Kits能够对JAK2 V617F/G1849T突变进行可靠的检测和半定量。只需按照试剂盒操作手册中的实验方案,即可便利的开始反应。
应用
ipsogen
JAK2 MutaScreen Kits能够对JAK2 V617F/G1849T突变进行可靠的检测和半定量,仅适用于科研。
辅助数据和图表
JAK2 mutation site identification.
JAK2 mutation site identification.
资源
试剂盒操作手册 (2)
ipsogen
JAK2 Muta
Screen
RS Handbook
EN
PDF
(2MB)
ipsogen
JAK2 Muta
Screen
Handbook
EN
PDF
(2MB)
安全数据表 (1)
Safety Data Sheets
EN
Download Safety Data Sheets for QIAGEN product components.
Certificates of Analysis (1)
Certificates of Analysis
EN
Safety Data Sheets (3)
ipsogen JAK2 MutaScreen RS Kit (19)
EN
ipsogen JAK2 MutaScreen Kit (24)
EN
ipsogen JAK2 MutaScreen Kit (10)
EN